|1.||Kohno, Shigeru: 5 articles (03/2015 - 01/2006)|
|2.||Bantar, C: 4 articles (06/2009 - 06/2000)|
|3.||Soutric, J: 4 articles (12/2002 - 06/2000)|
|4.||Yanagihara, Katsunori: 3 articles (12/2013 - 01/2006)|
|5.||Kara, Ateş: 3 articles (05/2011 - 10/2005)|
|6.||Falagas, Matthew E: 3 articles (04/2010 - 01/2007)|
|7.||Pachón, Jerónimo: 3 articles (03/2010 - 09/2006)|
|8.||Arenoso, H J: 3 articles (06/2009 - 06/2000)|
|9.||Fernandez Canigia, L: 3 articles (06/2009 - 06/2000)|
|10.||Juránková, J: 3 articles (12/2007 - 10/2003)|
04/01/2014 - "The data obtained in this study should be supported by further advanced in vitro and clinical studies to predict the accurate clinical efficacy of sulbactam containing combinations on A.baumannii infections. "
04/01/2001 - "These results show the efficacy of sulbactam in infections caused by susceptible strains of A. "
03/01/1990 - "Efficacy of sulbactam in an in vitro model of mixed aerobic/anaerobic infections."
04/01/2015 - "Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections."
07/01/2014 - "It has been found that sulbactam alone may be used to treat infections caused by A. "
06/01/2015 - "Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex."
12/01/2002 - "Chemother 2000; 12: 223-227) to assess the efficacy of amoxicillin/sulbactam (875 mg/125 mg), given orally twice-a-day for 7 days in the treatment of patients with community-acquired pneumonia (CAP). "
12/01/2002 - "Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia: a clinical trial based on a pharmacodynamic model."
12/01/1987 - "Efficacy of sulbactam-ampicillin in an induced Pasteurella haemolytica pneumonia model in calves."
03/01/2015 - "Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study."
|3.||Respiratory Tract Infections (Respiratory Tract Infection)
01/01/1988 - "A review of these studies indicates that therapy with sulbactam/ampicillin effectively treats lower respiratory tract infections in severely ill patients without causing serious adverse reactions."
07/01/1996 - "[Efficacy of sulbactam/cefoperazone in respiratory tract infections in elderly patients with underlying respiratory diseases]."
07/01/1995 - "[Clinical efficacy of sulbactam/cefoperazone for the treatment of geriatric patients with respiratory tract infections]."
10/01/1991 - "Clinical efficacy: in subjects with lower respiratory tract infections, sulbactam/ampicillin cured 32 patients (72.72%) and ameliorated the clinical status of 8 patients (18.18%); efficacy rate: 90.9%).(ABSTRACT TRUNCATED AT 250 WORDS)"
08/01/2001 - "This study suggests that amoxicillin/sulbactam (500mg/500mg) is still a suitable option for treating community-acquired lower respiratory tract infections, allowing a b.i.d. "
09/01/1993 - "Efficacy of cefoperazone in combination with sulbactam in experimental Staphylococcus aureus endocarditis in rabbits."
01/01/2005 - "The antibacterial therapy with cefoperazone/sulbactam in 9 patients was performed during the operation because of active infectious endocarditis. "
04/01/2001 - "In the endocarditis model, imipenem (t > MIC, 2.12 h) was more efficacious than sulbactam (t > MIC, 1.17 h) in bacterial clearance from vegetations. "
11/01/1990 - "A marked inoculum effect was demonstrated with sulbactam: effective concentrations of inhibitor needed to reduce the MIC and MBC of ceftriaxone to similar levels increased from 1 microgram/ml in the presence of an inoculum of 5 x 10(5) CFU/ml to 20 micrograms/ml in the presence of an inoculum of 1 x 10(7) CFU/ml. In vivo, sulbactam given at 200 mg/kg of body weight every 12 h, a dosage higher than that previously reported to be effective against rabbit endocarditis caused by other microorganisms, was not sufficient to restore the complete activity of ceftriaxone given at 30 mg/kg once daily for 4 days. "
04/01/2001 - "Sulbactam and imipenem were compared in an experimental pneumonia model in immunocompetent mice, using a susceptible strain of Acinetobacter baumannii, and in an experimental endocarditis model in rabbits, using an intermediately susceptible strain. "
|5.||Bacterial Infections (Bacterial Infection)
11/01/1986 - "The data support the intravenous administration of 12.5-25 mg of sulbactam/kg every 6 to 8 hr for assessing the adequacy of this drug as an adjunct to beta-lactam therapy for various bacterial infections in children."
04/01/1989 - "Clinical efficacy of sulbactam/ampicillin in the treatment of moderately severe bacterial infections."
06/01/1996 - "These studies have established the key role of sulbactam/ampicillin in the treatment of a wide variety of bacterial infections."
10/01/1984 - "[Clinical studies of sulbactam/cefoperazone therapy in pediatric bacterial infections]."
01/01/2008 - "Cefoperazone and sulbactam are prescribed in combination and used in the treatment of moderate to severe bacterial infections. "
|2.||Cefoperazone (Cefoperazone Sodium)
|2.||Vacuum Curettage (Vacuum Pump)
|5.||Cesarean Section (Caesarean Section)